Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haoli Yin

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Frontiers in Pharmacology|February 6, 2023
Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth <i>via</i> AR/GPX4 axis activated ferroptosisZhongqing Zhang, Tianlei Xie, Shun Zhang, et al.
Biomarker Research|July 13, 2022
circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3Haoli Yin, Haixiang Qin, Lei Yang, et al.
Journal of Hematology & Oncology|July 14, 2022
Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axisWenlong Zhang, Xin He, Haoli Yin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 4, 2021
Can <sup>68</sup>Ga-PSMA-11 PET/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy?Haoli Yin, Mengxia Chen, Xuefeng Qiu, et al.
Cell Death Discovery|May 3, 2022
circDHTKD1 promotes lymphatic metastasis of bladder cancer by upregulating CXCL5Qun Lu, Haoli Yin, Yongming Deng, et al.
Cancer Cell International|March 4, 2022
Pan-cancer analysis identifies LMNB1 as a target to redress Th1/Th2 imbalance and enhance PARP inhibitor response in human cancersHaixiang Qin, Yingqiang Lu, Lin Du, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Frontiers in Pharmacology|February 6, 2023
Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth <i>via</i> AR/GPX4 axis activated ferroptosisZhongqing Zhang, Tianlei Xie, Shun Zhang, et al.
Biomarker Research|July 13, 2022
circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3Haoli Yin, Haixiang Qin, Lei Yang, et al.
Journal of Hematology & Oncology|July 14, 2022
Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axisWenlong Zhang, Xin He, Haoli Yin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 4, 2021
Can <sup>68</sup>Ga-PSMA-11 PET/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy?Haoli Yin, Mengxia Chen, Xuefeng Qiu, et al.
Cell Death Discovery|May 3, 2022
circDHTKD1 promotes lymphatic metastasis of bladder cancer by upregulating CXCL5Qun Lu, Haoli Yin, Yongming Deng, et al.
Cancer Cell International|March 4, 2022
Pan-cancer analysis identifies LMNB1 as a target to redress Th1/Th2 imbalance and enhance PARP inhibitor response in human cancersHaixiang Qin, Yingqiang Lu, Lin Du, et al.
Pageof 2